XMT-1660

About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biotech company with a mission to deliver transformative ADCs to patients with cancer. Its core strategy is built on two proprietary technology platforms: Dolasynthen for creating homogeneous, cytotoxic ADCs and Immunosynthen for developing STING-agonist ADCs that engage the innate immune system. The company's most significant achievement is advancing its lead Dolasynthen candidate, UpRi, into a pivotal study for ovarian cancer, while also progressing earlier-stage clinical and preclinical assets. Mersana executes this strategy through internal R&D and strategic collaborations with larger pharmaceutical partners.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a mission-driven oncology company founded to address the systemic failure of traditional drug development to deliver timely therapies for children with cancer. The company's innovative 'Search & Development' model focuses on acquiring and developing promising clinical-stage or approved targeted therapies for high-unmet-need cancers. A major milestone was achieved in 2024 with the FDA approval of OJEMDA™ for pediatric low-grade glioma, transitioning Day One into a commercial entity and proving its unique operational strategy. The company is now leveraging this success to expand its pipeline through strategic acquisitions and internal development.

Therapeutic Areas